Ticker Report $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI) $PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00 $NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages $SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50 $RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00 $CERE Cerevel Thera...
Analysts believe AbbVie's early acquisition of Cerevel, despite high risks, could potentially yield high returns and avoid bidding wars if emraclidine's data is positive. It's also seen as a strategic move to enhance AbbVie's long-term pipelines.
Analyst Mohit Bansal opines AbbVie might favour purchasing Cerevel due to its perceived clean IP and daily dosing for its principal schizophrenia medication. He anticipates potential benefit from peak adjustments in sales surpassing $3B.
1 | Below is a look at the top insider trades with the biggest value in the past week. Last week, the major shareholder of$セレヴェル・セラピューティックス・ホールディングス(CERE.US)$, Bain Capital Investors Llc, purchased 5,480,052 shares worth $125 million in a transaction dated October 16th. The other two principal shareholders, Koppel Adam and Gordon Christopher, also bought an equivalent amount of stock at ...
15
2
3
報告
D Blaine :
Please add, if available, the percentage net change this represents. It adds important context.
セレヴェル・セラピューティックス・ホールディングスに関するコメント
Ticker Report in April
$WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
$PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00
$NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00
$CERE Cerevel Thera...
Alerted 22 hit 26
コラムWeekly Insider Money Tracking: Directors of Cerevel Therapeutics Buy Close to $400 Million Worth of Stock
Last week, the major shareholder of $セレヴェル・セラピューティックス・ホールディングス(CERE.US)$, Bain Capital Investors Llc, purchased 5,480,052 shares worth $125 million in a transaction dated October 16th. The other two principal shareholders, Koppel Adam and Gordon Christopher, also bought an equivalent amount of stock at ...
コラムUS Top Gap Ups and Downs on 4/24: CS, PHG, BIDU, HTHT and More
Gap Ups
1. $ロイヤルフィリップス(PHG.US)$ - up 13.10%
2. $ウィプロ(WIT.US)$ - up 2.0%
3. $フレゼニウス・メディカル・ケア(FMS.US)$ - up 1.5%
4. $Credit Suisse(CS.US)$ - up 1.1%
5. $エルビット・システムズ(ESLT.US)$ - up 1.1%
6. $セレヴェル・セラピューティックス・ホールディングス(CERE.US)$ - up 0.8%
7. $エイゴン(AEG.US)$ - up 0.7%
8. $トータルエネルギー(TTE.US)$ - up 0.4%...
Good news?
まだコメントはありません